150 results about "Antibody antigen" patented technology

Embodiments described herein relate to systems and methods for mapping molecules into interfaces. An example interface includes a visual interface having a map visualization. Example molecules include proteins, or any protein-like molecules or fragments thereof such as antibodies, antigens, proteins, lectins, receptors. Embodiments described herein relate to systems and methods for mapping molecules into interfaces by processing data using dimensionality reduction to generation representations of molecule maps (e.g. map visualizations).

The present invention discloses a hs-TnI detection method based on quantum dot microspheres, which directly reacts a sample with a first solution containing antibody 1 and a second solution containing antibody 2 to generate a sandwich structure complex of antibody 1-antigen-antibody 2, and the antigen and antibody react in a reaction cup, incubate at a constant temperature, and the reaction time is longer, and the reaction is more sufficient, which is conducive to the improvement of detection sensitivity. At the same time, during chromatography, with the high affinity of streptavidin and biotin, the complex obtained by the reaction can be better captured on the T line, so that the reaction can be made more sensitive, and the detection time is also faster relative to the existing reagent strips. Further, combined with the advantages of high sensitivity and wide linear range of quantum dot microspheres, detection repeatability (CV) is better, CV is increased from the traditional 15wt% to within 8wt%, and the detection sensitivity is as high as 2pg / ml, while the linear range is 2-30000pg / ml, and full coverage is achieved for low-concentration and high-concentration samples.

A protein interface prediction method based on three-track coding comprises the following steps: combining a fine-tuned protein language model SiteT5 with evolutionary, geometric and statistical features extracted from a sequence, sending the combined features into a three-track coding network, and integrating a cyclic gating module, a multi-resolution aggregation module and a long sequence deformation module to obtain a protein interface prediction model SiteT5; the method comprises the following steps: respectively capturing a time sequence relation, a local mode and long-range dependence among residues, respectively mapping the three codes into different weights, carrying out point multiplication on the three codes, and carrying out aggregation through a multi-view cross attention module; then the protein residues are sent to a three-layer hierarchical interactive learning module, local structure and global dependency are cooperatively mined through an eight-head gating self-attention module and a position-by-position feedforward module, and finally the probability that each protein residue is an interface is obtained through a classifier. According to the invention, a protein-DNA interface, a protein-RNA interface, a protein-protein interface and an antibody-antigen interface can be effectively captured. And the robustness is ensured, and meanwhile, relatively high prediction precision is also shown.

Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.

The invention provides an mRNA (messenger Ribonucleic Acid) or mRNA-LNP (Leucine Natriuretic Peptide) compound for coding antibody-antigen fusion protein and application thereof, and belongs to the technical field of cell therapy. Wherein the coding frame sequence of the mRNA comprises an antibody sequence, a cleavage sequence and an antigen peptide sequence; wherein the antibody targets a tumor high-expression surface protein, and the antigen is a high-immunogenicity antigen. According to the mRNA-coded antibody-antigen fusion protein, high-expression protein on the surface of a tumor cell is specifically recognized through an antibody, and a high-immunogenicity antigen is introduced into a recognized tumor target cell to mark the tumor cell. The mRNA can be ingested, processed and presented by antigen presenting cells so as to stimulate and activate antigen-specific TCR-T cells in vivo. Therefore, the widely labeled tumor cells can be specifically recognized and killed by the antigen-specific TCR-T cells in vivo.

Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.

Provided are an activity-regulatable IL-12 fusion protein and the use thereof. The fusion protein comprises a first structural unit, a second structural unit, and a third structural unit. The first structural unit is selected from a first Fc fragment, or a first antibody or an antigen-binding fragment thereof, wherein the first antibody or the antigen-binding fragment thereof has the binding activity to a tumor antigen or an immune checkpoint; the second structural unit is selected from a cleavable linker or a non-cleavable linker; and the third structural unit comprises an IL-12 cytokine or a functional fragment thereof. The second structural unit mediates the steric hindrance of the first structural unit to mask the activity of the IL-12 cytokine in the third structural unit, thereby reducing the toxic side effects of in-vivo use of the IL-12 cytokine. Compared with a wild-type IL-12, the fusion protein has the advantage of high safety, and can be further fused with an antibody Fab, scFv or VHH, an antigen-binding peptide or a recombinant protein, a polypeptide, etc. to obtain a multifunctional fusion protein that can be conditionally released and activated.

The application discloses a kind of vibration device for immunofluorescence method, belong to medical detection device field, the device adopts cavity, vibration unit, cooling device and sound insulation cotton, sound insulation cotton is used to reduce noise in experimental process, cooling device reduces the heat generated due to vibration, avoid the heat generated by vibration to cause the influence to sample;After energization, vibration unit forms a kind of vibration source, the vibration of slide in incubation box in cavity is driven by vibration, and then promote the exposure of fixed antigen / antibody epitope on slide, accelerate and antibody / antigen in incubation sample are combined, shorten incubation time, improve experimental efficiency.

This disclosure provides methods and apparatus for generating training data, training machine learning models, and analyzing biological samples. Generating training data includes: acquiring a first image of a biological sample; generating a first set of annotations for the first image based on a second image of the biological sample stained by a quantitative method that converts antibody / antigen complexes into dots; and outputting the first image and a benchmark truth including the first set of annotations as data for training a first machine learning model (“ML”) to analyze the biological sample. Furthermore, the generated (output) training data can then be used to train the ML model, and the trained ML model can be used to analyze the biological sample.

This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and / or ADC) to an ENPP1 polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and / or ADCs) that bind to an ENPP1 polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer (e.g., one or more sarcomas) are provided.

The invention relates to the technical field of medical adsorbents for blood perfusion, and discloses an application of a trans-cyclooctene group adsorbent based on a biological orthogonal reaction in preparation of a circulating tumor cell clearing preparation. The adsorbent adopts sephadex microspheres as a carrier, the surface of the carrier is modified with a trans-cyclooctene (TCO) group, a tetrazine (Tz) group is taken in by CTCs through modified mannose, the Tz group is expressed on the surface of a CTCs cell membrane in the form of glycoprotein through a Roseman-Warden pathway in cells, TCO and Tz are subjected to a biological orthogonal reaction specifically, and the adsorption capacity of the adsorbent is improved. The sephadex microsphere adsorbent can effectively enrich and remove CTCs in blood of the whole body of a patient through adsorption, and compared with a conventional single-antibody or multi-antibody capture technology, the sephadex microsphere adsorbent does not depend on antibody-antigen binding, and the capture efficiency of the CTCs can be remarkably improved through a biological orthogonal reaction.

The invention discloses an up-conversion nano-composite with a core-shell structure, a preparation method and application, and belongs to the technical field of biomedical bimodal nano-probes. According to the nanocomposite, up-conversion nanoparticles (UCNPs) serve as a core, metal-organic frameworks (MOFs) serve as a shell layer, horse radish peroxidase (HRP) is loaded on the shell layer, and UCNP (at) MOF / HRP is formed. Subsequent biological functional modification, such as coupling of an antibody, an antigen, nucleic acid and other substances, can be carried by an activating group or a metal coordination bond carried by a shell ligand of the upconversion nanocomposite MOF with the core-shell structure, so that the functions of specific recognition, targeted capture, specific loading and the like are realized.

The present disclosure relates to anti-glyco-cMET antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of cMET and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.

The present disclosure addresses the problem of providing a therapeutic agent for a disease in which formation of tertiary lymphoid tissue occurs in a lesion.　This prophylactic or therapeutic agent for a disease in which formation of tertiary lymphoid tissue occurs in a lesion contains an anti-CD153 antibody having cytotoxicity or an antigen-binding fragment of the antibody.

The present invention relates to the field of antibodies, antigen-binding fragments and immunodiagnosis. Specifically, the present invention relates to recombinant antibodies or antigen-binding fragments for binding thyroid hormone T4 (thyroxine) and halogenated bisphenol A. Furthermore, the present invention relates to isolated nucleic acid molecules comprising nucleotide sequences encoding the recombinant antibodies or antigen-binding fragments of the present invention, as well as expression vectors and host cells comprising the nucleic acid molecules of the present invention. In addition, the present invention relates to methods for producing recombinant antibodies or antigen-binding fragments for binding T4 thyroid hormone and halogenated bisphenol A, test kits and immunoassays comprising the recombinant antibodies or antigen-binding fragments of the present invention, and methods for determining the levels of T4 thyroid hormone and / or halogenated bisphenol A in a sample of a subject. Furthermore, the present invention relates to methods for processing samples, such as immunoaffinity-based sample preparation methods for enriching halogenated bisphenol A from a sample.

Methods for using antibodies, antigen-binding antibody fragments, immunoconjugates and pharmaceutical compositions for the treatment of adenoid cystic carcinoma, and pharmaceutical compositions containing immunoconjugates.

Embodiments described herein relate to systems and methods for mapping molecules into interfaces. An example interface includes a visual interface having a map visualization. Example molecules include proteins, or any protein-like molecules or fragments thereof such as antibodies, antigens, proteins, lectins, receptors. Embodiments described herein relate to systems and methods for mapping molecules into interfaces by processing data using dimensionality reduction to generation representations of molecule maps (e.g. map visualizations).

This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and / or ADC) to a CSPG4 polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and / or ADCs) that bind to a CSPG4 polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided.

Provided herein are antibodies, antigen-binding portions thereof, and antibody peptide conjugates that specifically bind to neuropilin-1 (NRP1) and various compositions of such antibodies, antigen-binding portions, and antibody-peptide conjugates. The disclosure also provides nucleic acids encoding the antibodies, antigen-binding portions thereof, or antibody peptide conjugates; cells comprising the nucleic acids; and methods for producing the antibodies, antigen-binding portions thereof, or antibody peptide conjugates. Also provided are methods for using the antibodies or antigen-binding portions thereof in therapeutics and diagnostics for cancer.

The invention relates to the technical field of biology, in particular to an SERS probe for Mfn2 detection, a preparation method of the SERS probe, an SERS sensor and application of the SERS sensor. Based on a surface enhanced Raman spectroscopy (SERS) technology, a gold nanoparticle SERS probe coated with an antibody 1 and a silver nanoparticle SERS probe coated with an antibody 2 are constructed, a sandwich structure is formed through combination of the antibody 1, an antigen and the antibody 2, the structure effectively improves SERS hot spot distribution and Mfn2 detection sensitivity, and traditional measurement steps are simplified. The constructed biologically coded SERS probe can be used for measuring Mfn2 with different concentrations. Based on the prepared SERS sensor, the dynamic measurement of the expression of the single living cell Mfn2 in the process of electrical stimulation of dental pulp stem cell odontogenic differentiation is realized, and the SERS sensor has wide clinical application prospect and transformation value in the aspects of measurement of protein molecules in a single cell organelle and diagnosis of Mfn2 related diseases.

The present invention relates to antigen binding molecules that specifically bind cellular bound fibroblast activation protein (cFAP). The antigen biding molecules significantly discriminate between cFAP and one or more soluble variants of fibroblast activation protein (FAP), including the one or more soluble variants of FAP known to be present in body fluids such as blood, plasma and serum. The antigen binding molecules comprise one or more antibodies and / or one or more antibody antigen binding domains or fragments, and, in particular, include one or more camelid single antigen binding domains, i.e. one or more VHH sequences. The present invention further relates to nucleic acid molecules encoding the antigen binding molecules or a component domain thereof, as well as vectors comprising said nucleic acid molecules. The invention also relates to a host cell comprising the vector(s) of the invention, as well as to methods for the production of an antigen binding molecule of the invention comprising culturing the host cell of the invention under suitable conditions and isolating the antigen binding molecule produced. Furthermore, the present invention relates to an antigen biding molecule obtainable by the method of the invention, to a composition comprising at least one of an antigen binding molecule of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the antigen binding molecule produced by the method of the invention. The present invention also relates to the use of an antigen binding molecule of the invention for detecting and targeting cFAP in vivo or in vitro, in particular selectively over one or more soluble variants of FAP, for use as a therapeutic in the treatment of diseases characterized by cFAP or as a diagnostic agent.

Predictive models are deployed to generate epitope predictions (e.g., B-cell epitopes). Predictive models analyze structural features of a protein, such as an antibody, or an antibody-antigen pair, and can identify epitopes and paratopes.

The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection in a subject. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a sarbecovirus and / or SARS-CoV-2 infection.

The invention discloses a tumor necrosis factor alpha detection kit using a chemiluminescence immunoassay technology, and relates to the technical field of detection kits. An anti-human tumor necrosis factor alpha antibody is used for coating a microporous ELISA plate, after a standard substance is added, the tumor necrosis factor alpha can be tightly combined with the coating antibody, then a detection antibody is added to form a stable antibody-antigen-enzyme-labeled antibody compound, free components are thoroughly removed through plate washing operation, then a chromogenic substrate TMB is added, and the detection sensitivity is high. The TMB is blue under the catalysis of a detection antibody, finally, the TMB is converted into yellow after a stop buffer is added, the depth of the color is positively correlated with the concentration of the tumor necrosis factor alpha in a sample, the absorbance is measured through an enzyme-linked immunosorbent assay instrument, the concentration of the sample can be accurately calculated, and the fixed seat can be prevented from shifting under the cooperation of a connecting shaft and a roller; and by arranging the bearing mechanism, the purposes of stretching out and storing the fixing mechanism can be achieved, and taking, placing and protection are facilitated.

The subject invention provides a composition comprising an enomomer which comprises a) a carrier molecule, and b) at least one aptamer, wherein the carrier molecule is an antibody, an antigen-binding moiety, a serum protein, an intracellular protein, a messenger RNA (mRNA) or human serum albumin.

The invention discloses a method for quantitatively detecting the content of PreScision protease by using a double-antibody sandwich. The method comprises the following steps: S1, coating an elisa plate with a capture antibody; s2, adding a sample to be detected into the coated elisa plate; s3, incubating by taking the HRP binding antibody as an enzyme-labeled antibody, developing by using a TMB developing solution, and detecting an OD value by using a microplate reader with the wavelength of 450 nm; and S4, drawing a standard curve by using the standard substance, and calculating the PreScision protease content in the detected sample according to the standard curve. According to the present invention, the antibody-antigen-antibody sandwich structure is formed through the double antibody sandwich, the SM17 is adopted as the capture antibody for coating, the SM10 is adopted as the detection antibody, the PreScision protease content is quantitatively detected through the obtained standard curve, and the sensitivity, the precision and the accuracy of the detection method provided by the present invention are maintained at the high level.

The application provides a set of methods for constructing antigen-antibody complex mutual recognition interface descriptors (i.e., protein molecular fingerprints), which maximally present the structure and physicochemical characteristics of specific recognition by describing the binding interface of the three-dimensional structure of the antibody-antigen from both sides. Based on the protein molecular fingerprints generated by the set of methods, based on the specific interaction recognition rules of the antigen-antibody, the epitope prediction algorithm specific to the antibody and the virtual screening model of the antibody are designed, and the existing machine learning or deep learning tools are docked, so that the antigen epitope prediction based on the antibody and the high-throughput virtual screening of the antibody based on the specific epitope can be quickly realized.

The present invention provides engineered antibodies and antigen binding fragments, in which an additional functional domain is inserted into the elbow region of the antibody or antigen binding fragment. The present invention also provides nucleic acid molecules, such as vectors, encoding such antibodies and antigen binding fragments, host cells and compositions comprising such antibodies, antigen binding fragments or nucleic acid molecules and uses thereof. For example a multispecific antibody format is provided, in which an additional binding site (specificity) is inserted into the elbow region of an antibody or antigen binding fragment.

Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates) thereof that bind CD73 are disclosed. The disclosure further relates to methods and compositions for use in the treatment of, e.g., cancer by administering the compositions provided herein.

This provides methods and materials involved in binding a molecule (e.g., an antibody, a fragment of an antibody, an antibody domain, a chimeric antigen receptor (CAR), a cell engager, or an antibody-drug conjugate (ADC)) to a B7 homolog 3 (B7-H3) polypeptide (e.g., a human B7-H3 polypeptide). For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, or ADCs) that bind to a B7-H3 polypeptide as well as methods and materials for using such binders to treat cancer are provided. Also provided are cells (e.g., host cells) designed to express one or more binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, or cell engagers) having the ability to bind to a B7-H3 polypeptide as well as methods and materials for using such cells to treat cancer.